Toggle navigation
PDFSEARCH.IO
Document Search Engine - browse more than 18 million documents
Sign up
Sign in
Back to Results
First Page
Meta Content
View Document Preview and Link
Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed/refractory chronic lymphoc
Add to Reading List
Document Date: 2015-08-06 13:19:29
Open Document
File Size: 149,58 KB
Share Result on Facebook
UPDATE
Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed/refractory chronic lymphoc